Research
We are contributing in the fight to eradicate cancer
We are using targeted lipid nanoparticles, TLNs, to selectively bring chemotherapy only to cancer and avoid healthy tissues. TLNs eradicate cancer with minimal adverse-effects. Our goal is to extend and enhance the quality of life of patients.
Delivering the Chemotherapy Only to Tumor
DoricPharma has a patented drug delivery platform that uses targeted lipid nanoparticles, TLNs, to deliver chemotherapeutics selectively only to tumors, sparing the healthy organs. TLNs maintain prolonged concentrations of chemotherapeutics in tumors while improving their therapeutic efficacy and reducing their adverse effects.
TLNs in Pancreatic Cancer
The TLNs drug delivery technology has been shown to target pancreatic tumors in mice, deliver the drug over an extended period of time, and significantly reduce or obliterate orthotopic or subcutaneous orthotopic tumors in mice.
The Team
Mike Nicolaou, PhD
CEO and Manager of Operations
Dr Nicolaou is a Pharmaceutical Chemist with 23 years of industrial experience in pharmaceutical industry. He has worked in the areas of product development, manufacturing and quality control and contributed to four new commercial pharmaceutical products in the areas of diabetes and metabolic diseases, and a vaccine product currently in clinical trials in the area of oncology.
